FK778 ameliorates post-transplant expression of fibrogenic growth factors and development of chronic rejection changes in rat kidney allografts

Nephrology Dialysis Transplantation

Volumn 23, Issue 11, 2008, Pages 3446-3455

  Rintala, Jukka M ^a   Savikko, Johanna ^a,b   Rintala, Sini E ^a   Von Willebrand, Eva ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

^b PÄIJÄT HÄME CENTRAL HOSPITAL   (Finland)

Author keywords

Acute rejection; Chronic allograft nephropathy; FK778; PDGF; TGF

Indexed keywords

2 CYANO 3 HYDROXY N [4 (TRIFLUOROMETHYL)PHENYL] 6 HEPTYNAMIDE; CYCLOSPORIN A; PLATELET DERIVED GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR A; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PLATELET DERIVED GROWTH FACTOR B; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; TACROLIMUS; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR;

ACUTE GRAFT REJECTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL DENSITY; CHRONIC ALLOGRAFT NEPHROPATHY; CHRONIC GRAFT REJECTION; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG POTENTIATION; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATION; KIDNEY ALLOGRAFT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LYMPHOCYTIC INFILTRATION; MACROPHAGE; MALE; MONOTHERAPY; NONHUMAN; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RAT STRAIN; RECEPTOR UPREGULATION; SCORING SYSTEM;

ALKYNES; ANIMALS; CALCINEURIN; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CYCLOSPORINE; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; GRAFT REJECTION; IMMUNOSUPPRESSIVE AGENTS; ISOXAZOLES; KIDNEY DISEASES; KIDNEY TRANSPLANTATION; MALE; NITRILES; PLATELET-DERIVED GROWTH FACTOR; RATS; RATS, INBRED WF; RISK FACTORS; TACROLIMUS; TRANSFORMING GROWTH FACTOR BETA; TRANSPLANTATION, HOMOLOGOUS;

EID: 54149098616     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfn340     Document Type: Article

References (21)

1. Meier-Kriesche HU, Ojo AO, Hanson JA et al. Increased impact of acute rejection on chronic allograft failure in recent era. Transplantation 2000; 70: 1098-1100
2. Joosten SA, Sijpkens YW, van Kooten C et al. Chronic renal allograft rejection: pathophysiologic considerations. Kidney Int 2005; 68: 1-13
3. Solez K, Axelsen RA, Benediktsson H et al. International standardization of criteria for the histologic diagnosis of renal allograft rejection: the Banff working classification of kidney transplant pathology. Kidney Int 1993; 44: 411-422
4. Hayry P, Isoniemi H, Yilmaz S et al. Chronic allograft rejection. Immunol Rev 1993; 134: 33-81
5. Shishido S, Asanuma H, Nakai H et al. The impact of repeated subclinical acute rejection on the progression of chronic allograft nephropathy. J Am Soc Nephrol 2003; 14: 1046-1052
6. Fitzsimmons WE, First MR: FK778, a synthetic malononitrilamide. Yonsei Med J 2004; 45: 1132-1135
7. Vanrenterghem Y, van Hooff JP, Klinger M et al. The effects of FK778 in combination with tacrolimus and steroids: a phase II multicenter study in renal transplant patients. Transplantation 2004; 78: 9-14
8. Bartlett RR, Dimitrijevic M, Mattar T et al. Leflunomide (HWA 486), a novel immunomodulating compound for the treatment of autoimmune disorders and reactions leading to transplantation rejection. Agents Actions 1991; 32: 10-21
9. Shawver LK, Schwartz DP, Mann E et al. Inhibition of platelet-derived growth factor-mediated signal transduction and tumor growth by N-[4-(trifluoromethyl)-phenyl]5-methylisoxazole-4-carboxamide. Clin Cancer Res 1997; 3: 1167-1177
10. Xu X, Shen J, Mall JW et al. In vitro and in vivo antitumor activity of a novel immunomodulatory drug, leflunomide: mechanisms of action. Biochem Pharmacol 1999; 58: 1405-1413
11. Savikko J, Von Willebrand E, Hayry P. Leflunomide analogue FK778 is vasculoprotective independent of its immunosuppressive effect: potential applications for restenosis and chronic rejection. Transplantation 2003; 76: 455-458; discussion 471-453
12. Deuse T, Schrepfer S, Schafer H et al. FK778 attenuates lymphocyteendothelium interaction after cardiac transplantation: in vivo and in vitro studies. Transplantation 2004; 78: 71-77
13. Schrepfer S, Deuse T, Schafer H et al. FK778, a novel immunosuppressive agent, reduces early adhesion molecule up-regulation and prolongs cardiac allograft survival. Transpl Int 2005; 18: 215-220
14. Lutz J, Huang H, Deng M et al. The effect of FK778 on the progression of chronic allograft nephropathy in a ratmodel. Transplantation 2007; 83: 741-746
15. Savikko J, Kallio EA, von Willebrand E. Early induction of platelet-derived growth factor ligands and receptors in acute rat renal allograft rejection. Transplantation 2001; 72: 31-37
16. Solez K, Colvin RB, Racusen LC et al. Banff '05 Meeting Report: differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy ('CAN'). Am J Transplant 2007; 7: 518-526
17. von Willebrand E, Zola H, Hayry P. Thrombocyte aggregates in renal allografts. Analysis with fine-needle aspiration biopsy and monoclonal antithrombocyte antibodies. Transplantation 1985; 39: 258-262
18. Racusen LC, Solez K, Colvin RB et al. The Banff 97 working classification of renal allograft pathology. Kidney Int 1999; 55: 713-723
19. von Willebrand E, Salmela K, Isoniemi H et al. Induction of HLA class II antigen and interleukin 2 receptor expression in acute vascular rejection of human kidney allografts. Transplantation 1992; 53: 1077-1081
20. Croker BP, Clapp WL, Abu Shamat AR et al. Macrophages and chronic renal allograft nephropathy. Kidney Int Suppl 1996; 57: S42-S49
21. Iwano M, Neilson EG. Mechanisms of tubulointerstitial fibrosis. Curr Opin Nephrol Hypertens 2004; 13: 279-284